Glickman Mark A 4
4 · TherapeuticsMD, Inc. · Filed Oct 15, 2021
Insider Transaction Report
Form 4
Glickman Mark A
Chief Business Officer
Transactions
- Award
Restricted Stock Units
2021-10-15+260,000→ 260,000 totalExercise: $0.00→ Common Stock (260,000 underlying) - Award
Performance Stock Units
2021-10-15+260,000→ 260,000 totalExercise: $0.00→ Common Stock (260,000 underlying) - Award
Restricted Stock Units
2021-10-15+400,000→ 400,000 totalExercise: $0.00→ Common Stock (400,000 underlying)
Footnotes (3)
- [F1]One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. No PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.
- [F2]Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer.
- [F3]Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on October 15, 2024, subject to the continued service of the reporting person with the issuer.